Multidrug resistance gene (MDR1) polymorphisms are associated with major molecular responses to standard-dose imatinib in chronic myeloid leukemia.

MLA

Dulucq, Stéphanie, et al. “Multidrug Resistance Gene (MDR1) Polymorphisms Are Associated with Major Molecular Responses to Standard-Dose Imatinib in Chronic Myeloid Leukemia.” Blood, vol. 112, no. 5, Sept. 2008, pp. 2024–27. EBSCOhost, https://doi.org/10.1182/blood-2008-03-147744.

APA

Dulucq, S., Bouchet, S., Turcq, B., Lippert, E., Etienne, G., Reiffers, J., Molimard, M., Krajinovic, M., & Mahon, F.-X. (2008). Multidrug resistance gene (MDR1) polymorphisms are associated with major molecular responses to standard-dose imatinib in chronic myeloid leukemia. Blood, 112(5), 2024–2027. https://doi.org/10.1182/blood-2008-03-147744

Chicago

Dulucq, Stéphanie, Stéphane Bouchet, Béatrice Turcq, Eric Lippert, Gabriel Etienne, Josy Reiffers, Mathieu Molimard, Maja Krajinovic, and François-Xavier Mahon. 2008. “Multidrug Resistance Gene (MDR1) Polymorphisms Are Associated with Major Molecular Responses to Standard-Dose Imatinib in Chronic Myeloid Leukemia.” Blood 112 (5): 2024–27. doi:10.1182/blood-2008-03-147744.